IQVIA艾昆纬：2025年司美格鲁肽在印度的专利到期：一个需要新策略的难得机会报告（英文版）

India's upcoming Loss of Exclusivity (LOE) for semaglutide marks a pivotal moment in global obesity care—one that is likely to defy traditional generics playbooks and demand bold, innovative strategies. With over 150 million potential patients, a fast-growing self-pay market, and early patent expiry, India creates a unique environment where both generics and innovators will shape new commercial and therapeutic norms. Unlike previous LOEs, this event is defined by rapid market evolution, r